Acesso livre
Acesso livre

Infectologia Pediátrica

OMS e parceiros chamam para uma ação urgente contra a meningite – Novas estratégias contra a meningite visam a salvar mais de 200.000 vidas anualmente.

1 Out, 2021 | 19:17h

Comunicado de imprensa: WHO and partners call for urgent action on meningitis – New meningitis strategy aims to save more than 200,000 lives annually – World Health Organization

Ver diretriz: Defeating meningitis by 2030: a global road map – World Health Organization

Comentários:

WHO Launches First Global Strategy to Eliminate Bacterial Meningitis by 2030 – Health Policy Watch

LSHTM joins WHO to call for urgent action on meningitis – London School of Hygiene & Tropical Medicine

 

Comentário no Twitter (fio – clique para saber mais)

 

Editorial | É hora de mandar as crianças de volta para a escola.

1 Out, 2021 | 18:49h

It’s time to send children back to school – Nature Medicine

Relatório do CDC | Escolas que não exigiram o uso de máscaras ficaram mais propensas a vivenciar surtos de Covid-19.

27 Set, 2021 | 13:26h

Association Between K–12 School Mask Policies and School-Associated COVID-19 Outbreaks — Maricopa and Pima Counties, Arizona, July–August 2021 – CDC Morbidity and Mortality Weekly Report

Comentário: Schools Without Mask Requirements More Likely to See COVID-19 Outbreaks – U.S. News

 

Comentário no Twitter

 

Estudo randomizado confirma que antibióticos são desnecessários para a maioria das crianças com infecção não complicada de trato respiratório baixo caso não haja suspeita clínica de pneumonia.

27 Set, 2021 | 12:37h

Antibiotics for lower respiratory tract infection in children presenting in primary care in England (ARTIC PC): a double-blind, randomised, placebo-controlled trial – The Lancet

 

Comentário no Twitter

 

Estudo randomizado de fase 1/2 | Segurança e imunogenicidade de vacina inativada contra COVID-19 (BBIBP-CorV) em crianças e adolescentes de 3 a 17 anos de idade.

27 Set, 2021 | 12:11h

Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial – The Lancet Infectious Diseases

Conteúdo relacionado: Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.

[Comunicado de imprensa – ainda não publicado] Pfizer anuncia que sua vacina contra COVID-19 produz forte resposta imune em crianças de 5 a 11 anos.

27 Set, 2021 | 11:00h

Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years – Pfizer and BioNTech

Comentários:

Covid-19 vaccine for 5- to 11-year-olds is safe and shows ‘robust’ antibody response, Pfizer says – CNN

Pfizer says COVID-19 vaccine safe, effective in younger children – CIDRAP

Pfizer Covid-19 vaccine generates robust antibody response in children, without serious safety issues, company says – STAT

Expert reaction to press release giving topline results from Pfizer and BioNTech from their phase 2/3 trial looking at safety and antibody responses from their COVID-19 vaccine in children aged 5 to 11 – Science Media Centre

 

Comentários no Twitter

(fio – clique para saber mais)

(fio – clique para saber mais)

 

Atualização de 2019 sobre COVID-19 e gestação.

27 Set, 2021 | 10:54h

An Update on Coronavirus Disease 2019 (COVID-19) and Pregnancy – American Journal of Obstetrics and Gynecology

Revisão | Sintomas de “long COVID” em crianças raramente persistem por mais de 3 meses.

20 Set, 2021 | 13:57h

Comunicado de imprensa: Long COVID symptoms in children rarely persist beyond three months –  Murdoch Children’s Research Institute

Estudo original: How Common Is Long COVID in Children and Adolescents? – The Pediatric Infectious Disease Journal

Comentário: Long Covid in children and adolescents is less common than previously feared – The Guardian

Conteúdos relacionados:

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Long COVID: the physical and mental health of children and non-hospitalized young people after SARS-CoV-2 infection – one in seven children may still have symptoms 15 weeks after infection.

Do kids get long COVID? And how often? A pediatrician looks at the data – Children also get Long Covid, but much less often than adults.

Illness duration and symptom profile in symptomatic school-aged children tested for SARS-CoV-2 – “Only 25 (1.8%) of 1379 children experienced symptoms for at least 56 days.”

Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents – “This study found a low prevalence of symptoms compatible with long COVID in a randomly selected cohort of children assessed 6 months after serologic testing”.

Study shows low incidence of post-acute COVID-19 symptoms (“Long Covid”) in children after mild disease

Cohort study: Risk factors for long covid in previously hospitalized children.

M-A: More than 50 long-term effects of COVID-19.

 

Comentário no Twitter (fio – clique para saber mais)

 

Perspectiva | Escolas começaram testagem em massa para COVID-19, mas obstáculos e incertezas permanecem.

17 Set, 2021 | 12:36h

Schools have begun mass testing for COVID-19. But hurdles and uncertainties remain – Science

Conteúdo relacionado: Cluster RCT: Daily contact testing of school-based contacts was non-inferior to self-isolation for control of COVID-19 transmission.

Estudo randomizado por cluster | Teste diário dos contatos de pessoas infectadas foi não-inferior ao autoisolamento para controlar a transmissão da COVID-19 nas escolas.

17 Set, 2021 | 12:12h

Daily testing for contacts of individuals with SARS-CoV-2 infection and attendance and SARS-CoV-2 transmission in English secondary schools and colleges: an open-label, cluster-randomised trial – The Lancet

Comentário convidado: Daily antigen testing to reduce disruption when schools return – The Lancet

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.